Sequana Medical NV's EBIT per Share for the
six
months ended in Jun. 2025 was €-0.10.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.90.
During the past 3 years, the average EBIT per Share Growth Rate was 26.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sequana Medical NV's EBIT per Share or its related term are showing as below:
FRA:2SE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -28.8 Med: -3.6 Max: 26.4
Current: 26.4
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Sequana Medical NV was 26.40% per year. The lowest was -28.80% per year. And the median was -3.60% per year.
FRA:2SE's 3-Year EBIT Growth Rate is ranked better than 71.59% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs FRA:2SE: 26.40
Sequana Medical NV (FRA:2SE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sequana Medical NV EBIT per Share Related Terms
Sequana Medical NV EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sequana Medical NV (FRA:2SE) has a EBIT per Share of €-0.90 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sequana Medical NV and its competitors. According to the industry distribution chart, Sequana Medical NV ranks #196 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 28.4%.
Is Sequana Medical NV's EBIT per Share too high?
Sequana Medical NV's current EBIT per Share is €-0.90. Based on the distribution chart, Sequana Medical NV ranks #196 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sequana Medical NV ranks #196 out of 690 companies for EBIT per Share. This puts Sequana Medical NV in the upper half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sequana Medical NV and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sequana Medical NV's current EBIT per Share is €-0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current EBIT per Share of €-0.90. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current EBIT per Share is €-0.90. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current EBIT per Share is €-0.90 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.
Key valuation signals for FRA:2SE:
EBIT per Share: €-0.90
GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score
Get the complete analysis for FRA:2SE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2SE has been successfully added to your 
